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Our studies found that BRCA1 levels negatively correlate with
DNA adducts induced by Benzo(a)pyrene (BaP). Pulse-chase
experiments showed that the increase in BaP-induced DNA
adducts in BRCA1 knockdown cells may not be associated with
BRCA1’s function in nucleotide excision repair activity; rather, it
may be associated with its function in modulating transcriptional
regulation. BRCA1 knockdown in MCF-10A cells signiﬁcantly
attenuated the induction of CYP1A1 following BaP treatment
indicating that the increase in BaP-induced adducts in BRCA1
knockdown cells is not CYP1A1 dependent. However, our study
shows that BRCA1 defective cells may still be able to biotransform
BaP by regulating other CYP enzymes, including CYP1B1.
Knockdown of BRCA1 also severely affected the expression levels
of two types of uridine diphosphate glucorunyltransferase
(UGT1A1 and UGT1A9) and NRF2. Both UGTs are known as
BaP-speciﬁc detoxiﬁcation enzymes, and NRF2 is a master
regulator of antioxidant and detoxiﬁcation genes. Thus, we
concluded that the increased amount of BaP-induced DNA
adducts in BRCA1 knockdown cells is strongly associated with
its loss of functional detoxiﬁcation. Chromatin immunoprecipita-
tion assay revealed that BRCA1 is recruited to the promoter/
enhancer sequences of UGT1A1, UGT1A9, and NRF2. Regula-
tion of UGT1A1 and UGT1A9 expression showed that the
induction of DNA adducts by BaP is directly affected by their
expression levels. Finally, overexpression of UGTs, NRF2, or
ARNT signiﬁcantly decreased the amount of BaP-induced
adducts in BRCA1-deﬁcient cells. Overall, our results suggest
that BRCA1 protects cells by reducing the amount of BaP-
induced DNA adducts possibly via transcriptional activation of
detoxiﬁcation gene expression.
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Growing evidence indicates that exposure to certain
environmental factors increases cancer risk. However, epide-
miologic studies have not yet demonstrated clear correlations,
in part, because human genetic variations may signiﬁcantly
affect individual susceptibility. Exposure to certain classes of
chemicals including polycyclic aromatic hydrocarbons (PAHs)
increases breast cancer risk (Dunnick et al., 1995). Benzo(a)-
pyrene (BaP) and 7,12-dimethylbenz(a)anthracene (DMBA)
are well-known potent carcinogenic PAHs, which are fre-
quently used to induce mouse skin and/or mammary gland
tumors (Luch, 2005). They require metabolic activation to
exert mutagenic and carcinogenic effects (Kouri et al., 1982;
Shou et al.,1 9 9 4 ). For example, BaP biotransformations are
frequently characterized as either phase I (metabolic activation)
or phase II (conjugation and detoxiﬁcation) (Williams, 1959;
Xu et al., 2005). In phase I, nonreactive BaP is activated into
more polar and water soluble intermediate metabolites (e.g.,
dione and dihydrodiol) that generate reactive oxygen species
and further oxidize to BaP-7,8-diol-9,10-epoxide (BPDE),
which can damage DNA and/or other macromolecules. In
phase II, these intermediate metabolites are conjugated into
more easily excreted forms by reactions such as glucuronida-
tion, sulfation, and glutathione conjugation (Williams, 1959;
Xu et al., 2005).
Aryl hydrocarbon receptor (AhR) is a phase I transcription
factor, which can bind the xenobiotic responsive element
(XRE) and direct transcription of several cytochrome P450s
(CYPs) and UDP-glucuronosyltransferases (UGTs) (Nebert
et al., 2000; Shen and Whitlock, 1992). Nuclear factor
(erythroid-derived 2)-like 2 (NRF2) is a phase II transcription
factor and induces cytoprotective enzymes such as glutathione
S-transferase (GST), several UGTs and multidrug resistance
proteins (Ko ¨hle and Bock, 2007).
BRCA1 is a tumor suppressor in ovarian and breast cancers
(Rosen et al.,2 0 0 3 ). Various functions of BRCA1 have been
identiﬁed including cell cycle progression, DNA repair, ubiquiti-
nation (as an E3 ubiquitin ligase), and transcription regulation
(O’Donovan and Livingston, 2010). BRCA1 plays a role in the
repairofDNAdouble-strandbreaks(Leeetal.,2000;Zhongetal.,
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microhomology-dependent DNA repair (Moynahan et al.,2 0 0 1 ;
Zhong et al.,2 0 0 2 ). A function of BRCA1 in nucleotide excision
repair (NER) of UV irradiation-induced DNA damage has been
proposed (Hartman and Ford, 2002), but its NER activity on
carcinogen-inducedDNAadductshasnotbeenwelldocumented.
BRCA1 affects transcription regulation activity by interacting
with multiple proteins including transcription factors (e.g., P53,
ERa, c-Myc). We recently reported that BRCA1 modulates
transcription regulation of stress-associated transcription factors
such as HIF-1a, AhR/ARNT, and NRF2 (Bae et al.,2 0 0 4 ; Kang
et al.,2 0 0 6 a , 2006b, 2008a).
In this study, we investigated whether BRCA1 has a pro-
tective function against carcinogen-induced DNA damage. We
found that abnormal BRCA1 levels or BRCA1 dysfunction
lead to detectably increased DNA damage after exposures to
certain xenobiotics (perhaps even after short exposures). In this
paper, we further investigate and discuss its potential molecular
mechanisms.
MATERIALS AND METHODS
Cell lines and reagents. A nearly normal-like human breast cell line,
MCF-10A, was obtained from American Type Culture Collection (Manassas,
VA). SUM149PT (BRCA1 2288delT) and SUM1315MO2 (BRCA1
185delAG) are two human breast cancer cell lines with mutations in the
BRCA1 gene (Elstrodt et al., 2006) and were purchased from Asterand Co.
(Detroit, MI). The growing media and conditions of MCF-10A, SUM149PT,
and SUM1315MO2 cell lines have been described in elsewhere (Elstrodt et al.,
2006). Benzo(a)pyrene (BaP) and DMBA were purchased from Sigma and
dissolved in dimethyl sulfoxide (DMSO). The [
3H]BaP and [c-
32P]ATP
radioisotopes were obtained from GE Healthcare (Piscataway, NJ).
siRNAs and DNA expression plasmids. The control (nontargeting
scrambled), BRCA1, XPA, ERCC1, UGT1A1, UGT1A9 (-1 and -2), and
NRF2 siRNAs were purchased from Dharmacon, Inc. (Lafayette, CO). The
following sequences of siRNAs were used for: Control-siRNA 5#-GAC GAG
CGG CAC GUG CAC A-3#, BRCA1-siRNA 5#-GAA GGA GCT TCC ATC
ATT C-3#, XPA-siRNA 5#-GCA AAT GGC TTC TAT CGA A-3#, UGT1A9-
siRNA-1 5#-GCA CAA GTA CGA AGT ATA T-3#, UGT1A9-siRNA-2 5#-
GCG AAC AAC ACG ATA CTT G-3#, NRF2-siRNA 5#-GAG TAT GAG
CTG GAA AAA C-3#. Smart pool siRNAs were used for UGT1A1- and
ERCC1-siRNA. The shRNA-coding DNA vectors (pSuper-control and pSuper-
BRCA1) were kindly provided by Dr Khanna (Fabbro et al., 2004). The
UGT1A1 and UGT1A9 expression plasmid DNA were purchased from
Origene Technology, Inc. (Rockville, MD).
[
3H]BaP-induced DNA adducts. Radioactivity of the [
3H]BaP-induced
DNA adducts was measured by liquid scintillation counter (Beckman Coulter,
Brea, CA) with the equal amounts of DNA (10 lg). Each radioactivity value
was subtracted by the nontreated background value to calculate the speciﬁc
radioactivity (cpm of adducts/cpm of total nucleotides 3 1/dilution factor) and
represents the number of DNA adducts per 10
6 nucleotides.
[
32P]postlabeling assays. This assay is a highly sensitive method to detect
and measure the amount of DNA adducts induced by carcinogens. MCF-10A
cells were transfected with 4 lg of BRCA1-shRNA for 72 h and treated with BaP
(5lM) or DMBA (1 or 5lM) for 24 h. Isolated genomic DNA (10 lg) was
incubated with a digestion mixture (10 units/ml micrococcal nuclease, 1.1 unit/ml
spleen phosphodiesterase, 25mM CaCl2, and 75mM sodium succinate [pH 6.0]) at
37 C for 4 h. After digestion, 50mM ammonium formate (pH 7.1) was added. The
solid phase extraction column (Varian, Inc., Harbor City, CA) was equilibrated
with methanol. After the sample was loaded onto the column, it was washed with
50mM ammonium formate (pH 7.1). The DNA adducts were eluted with 50%
methanol and were completely dried using a SpeedVac. Then the nuclease
P1 mixture (2 lg/ll nuclease P1, 0.15mM zinc chloride, 62.5mM sodium acetate
[pH 5.0]) was added and incubated at 37 C for 1 h. After incubation, 500mM Tris
base was added, and reaction mixture was dried. The adducts were labeled with
[
32P] in the mixture ([c-
32P]ATP [10 lCi/ll], T4 polynucleotide kinase, and
apyrase) at 37 C for 30 min. The labeled adducts were spotted on a thin layer
chromatography (TLC) sheet and developed in the following buffers. The BaP-
DNA adducts (Fig. 2b) were developed direction (hereafter, D1) (bottom to top) in
1.7M NaH2PO4 (pH 5.8) overnight; D3 (bottom to top) in 3.4M lithium formate
and 6.4M urea (pH 3.5) for 4 h; and D4 (left to right) in 0.8M NaH2PO4,0 . 5 M
Tris-HCl, and 7.5M urea (pH 3.5) for 4 h (Pan et al., 2006). The DMBA-DNA
adducts (Fig. 2c) were developed D1 (bottom to top) in 1M NaH2PO4 (pH 6.0) for
overnight; D3 (bottom to top) in 0.7M ammonium hydroxide for 4 h; and
D4 (left to right) in isopropanol:4M ammonium hydroxide (1.5:1) for 4 h
(Vadhanam et al., 2003). After development, the TLC was dried and exposed to
x-ray ﬁlm. The adduct spots were excised and placed in scintillation vials to
measure radioactivity using a liquid scintillation counter (Beckman Coulter).
Western blotting analysis. Whole cell lysates were separated by SDS-
PAGE, transferred to PVDF membranes (Millipore, Billerica, MA) for further
Western blotting (WB) analysis (Kang et al., 2006a). The anti-BRCA1 (C-20),
anti-XPA (FL-273), anti-ERCC1 (FL-297), anti-NRF2 (H-300), and anti-
ARNT (H-172) antibodies were purchased from Santa Cruz Biotechnology,
Inc. (Santa Cruz, CA). The anti-UGT1A9 (Novus Biologicals, Littleton, CO),
anti-UGT1A1 (BD Gentest, San Jose, CA), anti-CYP1A1 (Afﬁnity
BioReagents, Golden, CO), anti-CYP1B1 (BD Gentest), anti-ﬂag (M2,
Sigma-Aldrich, St Louis, MO), anti-GFP (Abcam, Cambridge, MA), and
anti-b-actin (Sigma-Aldrich) antibodies were obtained from different sources.
Antibody-protein complexes were visualized by enhanced chemiluminescence
(Santa Cruz Biotechnology, Inc.) using x-ray ﬁlms.
Semiquantitative RT-PCR. MCF-10A cells were pretreated with siRNA
(control vs. BRCA1) for 72 h and treated with 5lM of BaP for the indicated
time points in ﬁgures. Total RNAs were isolated with Trizol solution
(Invitrogen, Carlsbad, CA), and cDNA were prepared with Superscript II
reverse transcriptase (Invitrogen) according to the manufacturer’s instructions.
The following sequences of primers were used; BRCA1 forward 5#-TTG CGG
GAG GAA AAT GGG TAG TTA-3# and reverse 5#-TGT GCC AAG GGT
GAA TGA TGA AAG-3#, UGT1A1 forward 5#-CTC TTA AAT TTG AAG
TTT ATC CTG T-3# and reverse 5#-ACC ACA ACA CCA TTT TCT CC-3#,
UGT1A9 forward 5#-TGC TCA ATG GAA AGC ACA AG-3# and reverse
5#-CTG GCA CGA TTC CAA AAA CT-3#, NRF2 forward 5#-AAA CCA
CCC TGA AAG CAC AG-3# and reverse 5#-AGC GGC TTG AAT GTT TGT
CT-3#, CYP1A1 forward 5#-CTT GGA CCT CTT TGG AGC TG-3# and
reverse 5#-CGA AGG AAG AGT GTC GGA AG-3#, CYP1B1 forward
5#-CAC CAA GGC TGA GAC AGT GA-3# and reverse 5#-GAT GAC GAC
TGG GCC TAC AT-3#, b-actin forward 5#-GCT ATC CCT GTA CGC CTC
TG-3# and reverse 5#-ACA TCT GCT GGA AGG TGG AC-3#.
Ethoxyresoruﬁn-O-deethylase activity. CYP1A1 enzymatic activity was
measured using a CYP1A1 ethoxyresoruﬁn-O-deethylase (EROD) activity kit
(IKZUS Environment, Genova, Italy). MCF-10A cells were transfected with
aDNAvectorcontainingshRNA(pSuper-controlvs.pSuper-BRCA1)for72hand
treatedwithvariousdosesofBaP(0,1,2.5,5lM)for24h.Then,cellswerewashed
and incubated with reaction buffers (5lM of 7-ethoxyresoruﬁn and 10lMo f
dicumarol)for30min.Fluorescencewasmeasuredevery10minfor60minat37 C
with an Ultra 384 ﬂuorometer (Tecan, Switzerland) using 535 nm excitation and
590 nm emission ﬁlters as previously described (Kang et al.,2 0 0 8 b ).
Chromatin immunoprecipitation assays. MCF-10A cells were transfected
with siRNA (control vs. BRCA1) for 72 h and treated with 5lM of BaP for 30 or
60 min. Chromatin immunoprecipitation (ChIP) assays were performed using
BRCA1-REGULATED DETOXIFICATION 27a ChIP-IT assay kit (Active Motif, Carlsbad, CA) according to the manufacturer’s
instructions. The sheared chromatins were immunoprecipitated with normal
mouse IgG (the negative control), anti-BRCA1 (Ab1 þ Ab2 þ Ab3, EMD
chemicals, Gibbstown, NJ), and anti-ARNT (H-172, Santa Cruz Biotechnology,
Inc.) antibodies. Immunoprecipitated complexes were collected on Protein A/G
beads, and elutes were used as templates for semiquantitative RT-PCR or real-
time PCR. The following primer sequences were used to amplify XRE-
containing promoter regions; UGT1A9 promoter ( 2230 ~  2126 from
translation start site), 5#-CTG GTC TCG AAC TCC CGA CC-3# (forward)
and 5#-CCT TGG CCT CCC AAA GTG TAG G-3# (reverse); UGT1A1
promoter ( 3399 ~  3209 from translation start site), 5#-GTG TTA TCT CAC
CAG AAC AAA C-3# (forward) and 5#-TAC CCT CTA GCC ATT CTG-3#
(reverse) (Yueh and Tukey, 2007); NRF2 promoter ( 2878 ~  2749 from
translation start site), 5#-CAG AAG ACT TAC TTG ATG ATA-3# (forward)
and 5#-TGA GGC AGG AGA ATT GCT TGA-3’ (reverse).
Mammary gland organ culture. Female FBV Brca1
wt/wt and Brca1
co/co
mice carrying the MMTV-Cre were maintained in accordance with institutional
guidelines approved by the Georgetown University Animal Care and Use
Committee. Mice (3 weeks old) were primed with hormone pellets (estrogen þ
progesterone) (Innovative Research of America, Sarasota, FL) for 14 days. The
third mammary glands were removed and ﬂoated on gelatin sponges in 6-well
plates containing Waymouth’s MB 752/1 media, 100 unit/ml antibiotic-
antimycotic, 5 lg/ml insulin (bovine, lyophilized), 0.1 lg/ml aldosterone,
1 lg/ml luteotropic hormone, and 0.1 lg/ml hydrocortisone. After 2 days,
mammary glands were transferred to fresh media and treated with 5nM
[
3H]BaP for 24 h, and DNA-adduct formation was analyzed.
Pulse-chase assays. Cells were transfected with speciﬁc siRNAs (BRCA1,
XPA, ERCC1, UGT1A1, or UGT1A9-2) for 72 h and then treated with 5nM of
[
3H]BaP for 24 h. After removing free [
3H]BaP, fresh media were added. Then,
genomic DNA was isolated using Wizard SV Genomic DNA puriﬁcation system
(Promega, Madison, WI) after 0, 0.5, 1, 2, 4, or 8 h of medium change, then the
amount of [
3H]BaP-DNA adduct was measured by liquid scintillation counter.
XRE promoter construction and reporter gene assay. PCR reactions were
performed using pGL3-control vector as a template. All DNA sequences for
primers to amplify XRE for this study were used as follows; pGL3: 5#-ACC
AAC AGT ACC GGA ATG CC-3#; UGT1A1 XRE wt (1 copy): 5#-CGG ACT
TGA AGC TTG GCC AGC ACG CAA TGA ACA TTA CGC GTG CTA
GCC CGG GC-3#; UGT1A1 XRE mt (1 copy): 5#-CGG ACT TGA AGC TTG
GCC AGA CCG CAA TGA ACA TTA CGC GTG CTA GCC CGG GC-3#;
UGT1A9 XRE wt (2 copies): 5#-AGT ATA ATG GCG TGA TCT AGT ATA
ATG GCG TGA TCT TAC GCG TGC TAG CCC GGG C-3#; UGT1A9 XRE
mt (2 copies): 5#-AGT ATA ATG GCG GTA TCT AGT ATA ATG GCG
GTA TCT TAC GCG TGC TAG CCC GGG C-3#; NRF2 XRE wt (2 copies):
5#-AGT GCA GTG GCG TGA TCT AGT GCA GTG GCG TGA TCT TAC
GCG TGC TAG CCC GGG C-3#; NRF2 XRE mt (2 copies): 5#-AGT GCA
GTG GCG GTA TCT AGT GCA GTG GCG GTA TCT TAC GCG TGC TAG
CCC GGG C-3#. All underlined DNA sequences represent either putative wt or
mutant XRE. PCR products were subcloned into the pCR2.1-TOPO vector
(Invitrogen), and XRE-containing regions were excised using SacI and HindIII
restriction enzymes to be ligated into the pGL3-control vector. Luciferase
activity was measured using a luminometer, and the luminescence was
normalized for relative transfection efﬁciency by measuring b-galactosidase
activity of a cotransfected reporter plasmid (Kang et al., 2006a).
RESULTS
BRCA1 Levels Affect the Amount of DNA Adducts Induced by
Carcinogens (BaP or DMBA)
To test if wild-type (wt) BRCA1 protein levels affect the
amount of BaP-induced DNA adducts, cells were transfected
with DNA (empty vector vs. wt BRCA1) and treated with
[
3H]BaP for 24 h. Overexpression of wt BRCA1 in MCF-10A,
SUM149PT, and SUM1315MO2 cells signiﬁcantly decreased
the amount of DNA adducts induced by BaP (Fig. 1a). Next, in
SUM149PT cells, the effect of wt BRCA1 overexpression was
compared with the overexpression of four different mutant
BRCA1 proteins (T300G, C5365G, 5677insA, 5382insC).
None of the mutant BRCA1 proteins were as effective as wt
BRCA1 at reducing the amount of BaP-induced adducts
(Fig. 1b). We further investigated whether knockdown of
endogenous BRCA1 increases the amount of DNA adducts
induced by BaP. Indeed, BRCA1 knockdown signiﬁcantly
increased the amount of DNA adducts induced by BaP
according to [
3H]BaP concentration in MCF-10A (Fig. 2a).
To conﬁrm this result, we used an independent assay method,
the in vitro [
32P]postlabeling assay using TLC. Knockdown of
BRCA1 signiﬁcantly and reproducibly increased the amount of
adducts induced by BaP (about 4.5-fold) (Fig. 2b, the upper
right panel). As a positive control, BPDE (Fig. 2b, the lower
left panel) was used. The intensity of adduct spots detected by
the [
32P]postlabeling assay was signiﬁcantly higher in BRCA1
knockdown cells than control cells (Fig. 2b). When another
carcinogen, a known mammary gland tumor-inducing chem-
ical, DMBA, was used, larger effects on DNA adducts were
found (about 7-fold in 1lM of DMBA and 36-fold in 5lMo f
DMBA) (Fig. 2c). These results reinforce the conclusion that
BRCA1 levels inﬂuence the amount of adducts induced by
either BaP or DMBA. To test whether the increased BaP-
induced adducts could also occur in mammary gland tissue of
Brca1 conditional knockout mice, we used a whole mammary
gland organ culture assay. We found a 3- to 4-fold increase in
the amount of DNA adducts induced by BaP in the Brca1
knockout mice compared with controls (Fig. 2d).
BRCA1 Regulates the Amount of BaP-induced DNA Adducts
in NER-Independent Manner
Although BRCA1 has been shown to function in the NER
pathway following UV irradiation (Hartman and Ford, 2002),
there are limited reports linking BRCA1 mutations to defective
NER. Because few studies showed that DNA damage induced
by BPDE can be repaired by NER (Kennedy et al., 2005;
Motykiewicz et al., 2002; Shi et al., 2004), we tested whether
the increased amount of DNA adducts induced by BaP in
BRCA1 knockdown cells is due to the lack of NER activity.
Accordingly, we examined whether knockdown of the genes
encoding NER enzymes (XPA or ERCC1) with their speciﬁc
siRNAs can affect the amount of adducts induced by BaP.
Only slight increases (about 1.2- to 1.5-fold induction) in the
amount of BaP-induced adducts were observed in ERCC1
knockdown or both XPA and ERCC1 knockdown compared
with control-siRNA treated cells (data not shown). Next, we
performed pulse-chase experiments where the kinetics of DNA
adduct removal/repair was monitored after removing the
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3H]BaP from the culturing media. BaP-induced DNA adducts
were removed at the similar rate in both control-siRNA and
BRCA1-siRNA transfected cells (Fig. 3a). Extension of
detection time points (12 or 24 h after washing out the
[
3H]BaP) also showed a same pattern (data not shown). Similar
experiments were performed in XPA, ERCC1, or XPA þ
ERCC1 knockdown cells. There were signiﬁcantly decreased
rates in the amount of DNA adduct removal (Figs. 3b–d),
indicating that NER proteins are at least, in part, responsible for
repairing DNA damage induced by BaP. These data also
suggest that BRCA1 may not reduce BaP-induced DNA
adducts via NER activity. Our results indicate both NER and
non-NER (e.g., detoxiﬁcation) activities may be involved in
limiting DNA adducts induced by BaP.
BRCA1 Regulates Genes Encoding Metabolic Activation/
Detoxiﬁcation
Because the increased amount of BaP-induced DNA adducts
in BRCA1 knockdown cells cannot be explained by its DNA
repair activity, we examined whether BRCA1 regulates genes
involved in metabolic activation and/or detoxiﬁcation of BaP.
BRCA1 is known to regulate the expression of xenobiotic stress-
inducible genes such as CYP1A1 and CYP1B1 in MCF-7, an
estrogen receptor positive breast cancer cell line (Kang et al.,
2006a). Both CYP1A1 and CYP1B1 are known to be important
in metabolic activation in vitro.H o w e v e r ,in vivo, in a Cyp1a1
knockout mouse study, a potential important role for CYP1A1 in
detoxiﬁcation rather than metabolic activation of BaP is shown
(Uno et al.,2 0 0 4 ). In our study, we found that in MCF-10A cells
(estrogen receptor alpha negative), endogenous BRCA1 regu-
lates expression of CYP1A1 mRNA, protein, and enzymatic
activity (Fig. 4). On the other hand, another cytochrome p450
enzyme, CYP1B1 mRNA and protein expression were less
affected by BRCA1 knockdown (Figs. 4a and 4b). Several
enzymes including GST, sulfotransferase (SLT), and UGT
families are reported to detoxify BaP metabolites (Fang et al.,
2002). We were particularly interested in UGT1A1, UGT1A9,
and NRF2 genes, all of which contain XRE on their promoters
or enhancers. The two UGT genes, UGT1A1 and UGT1A9,
have been reported as the only two major hepatic enzymes
among UGTs that detoxify BaP metabolites (Fang et al.,2 0 0 2 ).
The mRNA of NRF2 has been reported to be regulated by 2, 3,
7, 8-tetrachlorodibenzo-p-dioxin via AhR/ARNT (Miao et al.,
2005), and its protective function against various carcinogens
has been well documented (Kwak and Kensler, 2010). As
expected, signiﬁcant decreases in basal expression level of
UGT1A1, UGT1A9, and NRF2 were found in BRCA1
knockdown cells (Fig. 5). Time course studies demonstrated
that BaP increased UGT1A1 and UGT1A9 mRNA and protein
FIG. 1. Overexpression of BRCA1 decreases the amount of DNA adducts induced by BaP. (a) wt BRCA1 overexpression decreases the amount of DNA
adducts induced by [
3H]BaP in human BRCA1 mutated breast cancer cell lines, SUM149PT and SUM1315MO2, as well as the nearly normal-like human breast
cell line, MCF-10A. All three breast cell lines were transfected with expression vectors (pCDNA3 vs. pCDNA3-BRCA1) overnight and were cultured for an
additional 24 h in 2.5 or 5nM of [
3H]BaP. Analysis by WB demonstrated wt BRCA1 overexpression in MCF-10A cells. (b) Exogenously expressed wt BRCA1 or
mutant BRCA1(s) differentially affect(s) the amount of DNA adducts induced by BaP in SUM149PT cells. Cells transfected with various BRCA1 expression
vectors were treated with 5nM of [
3H]BaP for 24 h, and radioactivity levels were determined. Analysis by WB was done using an anti-BRCA1 antibody to assure
that the differential effects on the amount of BaP-induced adducts were not due to differential BRCA1 expression levels. b-Actin was used as a loading control.
Student’s t-tests were applied for statistical signiﬁcance; (*) is p < 0.05 and (**) indicates p < 0.01.
BRCA1-REGULATED DETOXIFICATION 29expression in the presence of BRCA1, but the induction was
attenuated in BRCA1 knockdown cells (Fig. 5). In compar-
ison, BaP induces NRF2 protein levels without increasing its
mRNA levels, and the induction of NRF2 protein is also
signiﬁcantly attenuated in BRCA1 knockdown cells (Fig. 5c).
Together, these experiments show that BRCA1 plays an
important role in the regulation of xenobiotic stress-inducible
gene expression, which inﬂuences the levels of DNA adducts
induced by carcinogens.
Abrogation of BRCA1 Decreases ARNT Binding to XRE and
BaP-Induced XRE Promoter Reporter Activity
Because BRCA1 physically binds ARNT and enhances
xenobiotic stress-induced gene regulation activity (Kang et al.,
2006a), we investigated whether BRCA1 and/or ARNT can be
found on XRE-containing promoter/enhancer regions of
UGT1A1, UGT1A9, and NRF2 using ChIP assay. To
demonstrate that BRCA1 is recruited to XRE regions with
ARNT following BaP treatment and that BaP-mediated ARNT
recruitment to XRE is affected by the level of endogenous
BRCA1, cells were pretreated with siRNA (control vs.
BRCA1) and treated with 5lM of BaP for 30 or 60 min. As
expected, we found that BRCA1 and ARNT proteins were
signiﬁcantly recruited to the endogenous genomic UGT1A1,
UGT1A9, and NRF2 promoter after BaP treatment, but these
recruitments were signiﬁcantly decreased in BRCA1 knock-
down cells (Figs. 6a and 6b). These results suggest that
BRCA1 may be functionally and physiologically important for
UGT1A1, UGT1A9, and NRF2 transcriptional regulation. In
order to test whether BRCA1 affects gene expression via XRE
binding, we constructed luciferase reporters containing wt or
mutant XREs from the three genes. Reporter gene assays show
that overexpression of BRCA1 enhances the basal and BaP-
mediated wt XRE-containing promoter activity of all three
genes (Fig. 6c). On the other hand, no activation was found in
all three reporters containing mutant XRE sequence, suggesting
that BRCA1 and BaP activate the transcription of XRE-
containing genes. Meanwhile, knockdown of BRCA1 signif-
icantly decreased the BaP-induced XRE reporter activity of
UGT1A1 and NRF2 (Fig. 6d). Interestingly, the UGT1A9-
XRE-Luc reporter activity rather increased in BRCA1
knockdown cells regardless of BaP treatment. This indicates
FIG. 2. BRCA1 knockdown or knockout increases the amount of DNA
adducts induced by carcinogens (BaP or DMBA). (a) BRCA1 knockdown
increases the amount of DNA adducts induced by [
3H]BaP in MCF-10A cells.
Cells were transfected with shRNA coding vector (pSuper-control vs. pSuper-
BRCA1) for 72 h and then treated with 2.5 or 5 nM of [
3H]BaP for an
additional 24 h. (b) The effect of BRCA1 knockdown on the amount of adducts
induced by BaP was measured by the [
32P]post labeling method. MCF-10A
cells transfected with DNA vectors containing shRNA for 72 h were treated
with 5 lM of BaP for 24 h. Genomic DNA was isolated, [
32P]post labeled, and
analyzed by a TLC. BPDE was used as a positive control. (c). The effect of
BRCA1 knockdown on the amount of DMBA-induced adducts. A similar
experiment as in (b) was performed except with DMBA. The radioactivity of
BaP- or DMBA-induced DNA adduct spots from BRCA1 knockdown cells was
measured by scintillation counter and compared with controls as mean of
relative radioactivity ± S.E. (d) The increase in DNA adducts induced by
[
3H]BaP in cultured whole mammary glands of Brca1 conditional knockout
mice (co/co). The third mammary glands from BRCA1
wt/wt (wt/wt) and
BRCA1
co/co (co/co) mice were treated with 5 nM of [
3H]BaP for 24 h and then
assayed to measure the amount of DNA adducts. The data presented in (a)
and (d) are as the mean of the number of DNA adducts per 10
6 nucleotides ±
S.E of three independent experiments. Student’s t-tests were applied for
statistical signiﬁcance; (*) is p < 0.05 and (**) indicates p < 0.01.
30 KANG ET AL.that either (1) BRCA1 binding to UGT1A9 (shown by ChIP
assay) may not be as crucial as UGT1A1 or NRF2 or
(2) unidentiﬁed factors activated by BRCA1 knockdown may
stimulate the UGT1A9 promoter reporter. Thus, we found that
BRCA1 binds to the XRE-containing promoter region of
UGT1A1, UGT1A9, and NRF2 and regulates their promoter
reporter activities in an XRE-dependent manner.
Restoring UGT1A1 and UGT1A9 Decreases the Amount of
Adducts Induced by BaP in BRCA1 Knockdown Cells
The function of UGTs in detoxiﬁcation has been studied
mainly in in vitro enzymatic assays. In order to demonstrate
the intracellular BaP-detoxiﬁcation functions of UGT1A1 and
UGT1A9, cells were pretreated with siRNA (control,
UGT1A1, or UGT1A9) for 72 h and treated with [
3H]BaP
for 24 h. Increased amounts of BaP-induced adducts were
found in either UGT1A1 (Fig. 7a)o rU G T 1 A 9( Fig. 7b)
knockdown cells. Because there were no differences in the
[
3H]BaP removing rate (Fig. 7c), we believe that the increased
amount of adducts induced by BaP in UGT knockdown cells
is due to the loss of their detoxifying function. To further
conﬁrm whether the increase in BaP-induced adducts in
BRCA1 knockdown cells are partially due to the decreased
expression of UGT1A1 and UGT1A9, we overexpressed the
two UGTs (independently or simultaneously) in BRCA1
FIG. 3. Kinetics of BaP-DNA adducts removal in BRCA1 and NER
knockdown cells. (a) Pulse-chase experiments were used to monitor the effect
of BRCA1 status on the removal of DNA adducts induced by [
3H]BaP. MCF-
10A cells were transfected with the shRNA containing vector for 72 h and
treated with 5nM of [
3H]BaP for 24 h. Cells were then washed and incubated in
fresh media for the indicated times and the remaining levels of [
3H]BaP adducts
were measured. (b–d) Pulse-chase experiments were performed as in (a) to
monitor the effect of XPA (b), ERCC1 (c), or XPA þ ERCC1 (d) knockdowns
(using chemical siRNA) on the removal of [
3H]BaP-induced DNA adducts.
(e) Knockdowns of each gene (XPA or ERCC1) were conﬁrmed by WB
analysis. Student’s t-tests were applied for statistical signiﬁcance; (*) and (**)
indicate p < 0.05 and p < 0.01, respectively.
FIG. 4. Effect of endogenous BRCA1 on CYP1A1 and CYP1B1 gene,
protein, and EROD activity. MCF-10A cells were pretreated with siRNA
(control vs. BRCA1), treated with BaP and harvested for (a) CYP1A1 and
CYP1B1 mRNA, (b) CYP1A1 and CYP1B1 protein, and (c) CYP1A1
enzymatic activity. Bar graphs show the results of semiquantitative RT-PCR
(a) and WB (b) results of three independent experiments quantiﬁed by
densitometry. Student’s t-tests were applied for statistical signiﬁcance; (*) is
p < 0.05 and (**) indicates p < 0.01.
BRCA1-REGULATED DETOXIFICATION 31knockdown cells and found that each of the UGTs can
signiﬁcantly decrease the amount of adducts induced by BaP
(Fig. 7d). These ﬁndings strongly suggest that the intracellular
amounts of these UGTs are important for determining the
extent to which mutagenic BaP metabolites are able to induce
DNA damages, at least, in MCF-10A cells. When the two
UGTs were transfected simultaneously, no additive or
synergistic effects on reducing BaP-induced adducts in
BRCA1 knockdown cells were found (Fig. 7d). In these
experiments, we conﬁrmed that the two BaP-detoxiﬁcation
enzymes or NRF2 are important in the BaP-DNA metabolite
detoxiﬁcation process. In addition, we found that the
increased amount of BaP-induced adducts in BRCA1
knockdown cells are partially due to the reduced levels of
UGTs, NRF2, and ARNT expression.
Restoring ARNT and NRF2 Signiﬁcantly Decreases the
Amount of DNA Adducts Induced by BaP in BRCA1
Knockdown Cells
Because knockdown of BRCA1 caused the decrease in
basal expression or induction of ARNT and NRF2 protein
(Fig. 8a), we determined to test whether restoring ARNT or
NRF2 could decrease the amount of BaP-induced DNA
adducts in BRCA1 knockdown cells. When either ARNT or
NRF2 was overexpressed in BRCA1 knockdown cells, the
amount of DNA adducts induced by BaP was signiﬁcantly
decreased (Figs. 8b and 8c), suggesting that these two
transcription factors are important in controlling the amount
of BaP-induced DNA adducts. In addition, we found
signiﬁcantly increased amounts of BaP-induced DNA adducts
when ARNT or NRF2 was knockdowned by siRNAs in
MCF-10A cells (data not shown).
DISCUSSION
Our ﬁndings suggest that BRCA1 levels affect the amount of
DNA adducts induced by carcinogens such as BaP or DMBA
and that this effect is potentially a function of transcriptional
FIG. 5. BRCA1 regulates the expression of endogenous UGT1A1, UGT1A9, and NRF2. Differential gene expression of UGT1A1, UGT1A9, or NRF2 in
the presence and absence of endogenous BRCA1 was determined by semiquantitative RT-PCR and WB analysis. (a) BRCA1 levels affect the mRNA level of
UGT1A1, UGT1A9, and NRF2 following BaP. Cells were pretreated with siRNA (control vs. BRCA1) for 72 h, treated with 5lM of BaP, and harvested at the
indicated time points. The agarose gel image is a representative of three independent experiments. (b) Mean ± SE values from three independent
semiquantitative RT-PCR assays were plotted to compare relative level of each transcript. (c) Cells were pretreated with siRNA (control vs. BRCA1) for 72 h,
treated with 5lM of BaP (0, 2, 4, or 8 h), and harvested for WB analysis. (d) Mean ± SE values from three independent WB analysis were plotted to show
relative intensity values of each band as determined by densitometry. Student’s t-tests were applied for statistical signiﬁcance. Symbols (*) and (**) indicate p <
0.05 and p < 0.01 (control- vs. BRCA1-siRNA in the same concentration of BaP), respectively; Symbols (
#) and (
##) indicate p < 0.05 and p < 0.01 (no
treatment vs. BaP treatment in control-siRNA), respectively.
32 KANG ET AL.regulation of genes involved in metabolic activation and/or
detoxiﬁcation and not NER.
Because activated xenobiotics are capable of damaging
DNA, our results raised the possibility that BRCA1 defects
may play a more immediate, acute, and direct role in generating
carcinogen-induced mutations by locally increasing the
potency of carcinogens. This possibility has not been pre-
viously systematically investigated because it is generally
assumed that the acute short-term DNA damaging and/or
mutagenic effects of a ﬁxed concentration from xenobiotic
FIG. 6. BRCA1 is recruited to UGT1A1, UGT1A9, and NRF2 promoter/enhancer sequences. (a) ChIP assays were performed to determine the effect of
BRCA1 knockdown on promoter occupancy by UGT1A1, UGT1A9, and NRF2. Fragmented genomic DNA from MCF-10A cells, which had been pretreated with
siRNA for 72 h and then treated with 5lM BaP for 30 or 60 min, was immunoprecipitated by anti-BRCA1 and anti-ARNT antibodies. (b) RT-PCR of (a) results.
Student’s t-tests were applied for statistical signiﬁcance; (
#) and (
##) indicate p < 0.05 and p < 0.01 (no treatment vs. BaP treatment in control-siRNA), respectively
and (*) p < 0.05 and (**) p < 0.01 (control-siRNA vs. BRCA1-siRNA), respectively. (c) The effects of BRCA1 overexpression on BaP-induced UGT1A1,
UGT1A9, and NRF2 promoter reporter activity (XRE and mutant XRE [mXRE]). Cells were transfected with the reporter gene and expression vector and treated
with either DMSO or BaP for 24 h. (d) Effects of BRCA1 knockdown on BaP-induced reporter activity of UGT1A1, UGT1A9, and NRF2 promoter. Cells were
pretreated with siRNA for 48 h, transfected with a reporter plasmid, and then treated with 5lM BaP for 24 h. Student’s t-tests were applied for statistical
signiﬁcance; (*) and (**) indicate p < 0.05 and p < 0.01 (control-siRNA vs. BRCA1-siRNA), respectively.
BRCA1-REGULATED DETOXIFICATION 33carcinogens (e.g., BaP) are not signiﬁcantly affected by
BRCA1 defects. However, our results open a new avenue of
investigation with respect to BRCA1’s role in reducing
carcinogen-induced short-term DNA damage.
Currently, measurement of increased levels of carcinogen-
DNA adduct formation is a generally acceptable marker for
carcinogen studies (Kriek et al.,1 9 9 3 ; Poirier, 1997). Thus far,
BPDE has been widely used to study the relationship between
carcinogens and DNA repair because BPDE, an ultimate
metabolic form of BaP, directly binds DNA and causes DNA
damage. Studies have demonstrated that deﬁcient DNA repair
capacity (particularly NER) is associated with increased breast
cancer risk using BPDE as a DNA damage inducer (Kennedy
et al.,2 0 0 5 ; Motykiewicz et al.,2 0 0 2 ; Shi et al.,2 0 0 4 ). In this
study, we used BaP as a carcinogen since we were particularly
interestedinenvironmentalfactorstowhichweareroutinelybeing
exposed and that require biotransformation to become active
carcinogens.
Although it is known that BRCA1 plays a role in repairing
DNA double-stranded breaks by homologous recombination,
few studies have documented the potential of BRCA1 in DNA
single-strand break repair (Hartman and Ford, 2002; Saha
et al., 2010). Studies have demonstrated that BRCA1 activity
participates in transcription-coupled repair, a subpathway of
NER (Abbott et al., 1999; Le Page et al., 2000) whose
mechanism is verycomplexandnotwellunderstood(Fengetal.,
2002). BRCA1 is also associated with the human chromatin
remodeling complex (SWI/SNF-related complex), which can
affect gene expression and/or DNA repair (Bochar et al., 2000).
A recent study showed that treatment with histone deacetylase
inhibitor, trichostatin A, increases radiation-induced DNA
damage and slows down the repair kinetics using HCC1937,
a BRCA1 mutant cell line (Zhang et al., 2007), suggesting
a potential role of BRCA1 in chromatin remodeling. This
evidence combined with the data from this study underscore the
necessity of further studies to investigate the exact role(s) of
BRCA1 in inﬂuencing the level of DNA adducts induced by
carcinogens.
In this study, we have shown that BRCA1 is required for
normal induction or maintenance of constitutive levels of genes
coding for both metabolic activation enzymes (e.g., CYP1A1)
and detoxiﬁcation enzymes (e.g., UGTs). However, under
carcinogenic stress, such as BaP, it is puzzling as to why there
are increased amounts of DNA adducts in BRCA1-defective
cells or tissues. Although CYP1A1 has the greatest capacity for
initiation of BaP metabolism, CYP1B1 also plays a major role
in the metabolic activation pathway (Kim et al., 1998).
Because a substantial amount of CYP1B1 protein still
expresses even after BRCA1 knockdown in MCF-10A cells,
BaP may be metabolically activated via either CYP1B1 or
other CYP1 family of proteins or unidentiﬁed metabolic
enzymes in these cells. On the other hand, a signiﬁcant delay or
defect in eliminating increased amounts of BaP-induced
adducts observed in BRCA1 knockdown cells can correlate
with decreased expression and induction of detoxiﬁcation
enzymes (e.g., UGTs) and NRF2. Perhaps, the tight coupling
and sequential activation of detoxiﬁcation genes following
metabolic activation gene expression may be important for an
adequate detoxiﬁcation process.
Our results show that BaP induces CYP1A1, CYP1B1,
UGT1A1, and UGT1A9 mRNA expression without altering
FIG. 7. UGT1A1 or UGT1A9 regulates the amount of DNA adducts
induced by BaP. (a, b) Effect of UGT1A1- or UGT1A9-siRNA on the amount
of BaP-induced adducts. Cells were pretreated with siRNAs for UGT1A1 (a) or
UGT1A9 (b) for 72 h and treated with 2.5, 5, or 10nM of [
3H]BaP for 24 h.
Knockdown of UGTs was conﬁrmed by WB analysis (right panels).
(c) Kinetics of removal of DNA adducts induced by [
3H]BaP in UGT1A1 or
UGT1A9 knockdown cells. Pulse-chase experiments were performed to
determine effects of UGT1A1 or UGT1A9 knockdown on the removal of
[
3H]BaP-DNA adducts. (d) Restoring UGT1A1 and/or UGT1A9 genes
decreased the amount of BaP-induced DNA adducts in BRCA1 knockdown
MCF-10A cells. Cells transfected with shRNA-coding vector (control vs.
BRCA1) for 48 h were transfected with 1 lg of expression vectors for either
UGT1A1 or UGT1A9 or both for an additional 24 h. The transfected cells were
further treated with 5nM of [
3H]BaP for 24 h, and the amount of DNA adducts
was measured. Student’s t-tests were applied for statistical signiﬁcance;
(**) indicates p < 0.01 (a, b, and d).
34 KANG ET AL.NRF2 mRNA expression levels. On the other hand, BaP does
increase NRF2 protein expression level. This may be due to
a posttranslational modiﬁcation of NRF2, which has been
reported as a major mechanism of its regulation in oxidative
stress responses in vitro (Kwak and Kensler, 2010).
Similarly, we demonstrated the signiﬁcance of Brca1 levels
in determining the amount of BaP-induced DNA adducts only
in ex vivo experiments using Brca1
wt/wt and Brca1
co/co mice.
There are only a few reports on the function of Brca1 in
carcinogenesis in in vivo models. Dr Deng’s group has shown
that oxidative stress and a carcinogen (methyl-N-amylnitros-
amine) allows the formation of esophagus and forestomach
cancer in mice that are homozygous for full-length Brca1
deletion and heterozygous for a p53-null mutation (Brca1
D11/
D11p53
(þ/ ))( Cao et al.,2 0 0 7 ). Because breast and ovary are
the major organs affected by BRCA1 defects, it will be worthy
toextendourstudieswithamammarygland-speciﬁclaboratory
carcinogen such as DMBA. In addition, mammary gland-
speciﬁc conditional Brca1 knockout mice can be used to
determine whether the speciﬁc carcinogen, DMBA, induces
mammaryglandtumors.Thus,futuredevelopmentofaninvivo
carcinogenesis model will elucidate the complete function of
BRCA1 in environmental risk.
An in vivo model will be profoundly useful in evaluating the
human condition. The effect of cigarette smoking on the risk of
breast cancer among carriers of BRCA1 and/or BRCA2
FIG. 8. Effects of restoring ARNT or NRF2 on BaP-induced DNA adducts in BRCA1 knockdown cells. (a) Cells were pretreated with siRNA (control vs.
BRCA1), treated with BaP (0, 2.5, and 5lM), harvested, and conﬁrmed by WB analysis using anti-BRCA1, anti-NRF2, and anti-ARNT antibodies.
(b) Overexpression of ARNT in BRCA1 knockdown cells decreases the amount of adducts induced by BaP. Cells transfected with shRNA coding vector
(pSuper-control vs. pSuper-BRCA1) for 48 h were transfected with GFP-tagged ARNT (vs. pEGFP as a empty vector) and then treated with [
3H]BaP for 24 h.
(c) Restoring NRF2 reduced the amount of DNA adducts in BRCA1 knockdown cells. Cells were transfected with shRNA as in (a) and infected with
adenovirus (Ad)-ﬂag-NRF2 (vs. Ad-Null) and then [
3H]BaP-DNA adducts were measured. Student’s t-tests were applied for statistical signiﬁcance; (*) and
(**) indicate p < 0.05 and p < 0.01, respectively. Far right panels of (b) and (c) show the results of WB analysis after restoring either GFP-ARNT or Ad-ﬂag-
NRF2 in BRCA1 knockdown cells.
BRCA1-REGULATED DETOXIFICATION 35mutation is still controversial. Some studies showed reduced
(Brunet et al.,1 9 9 8 ) or no effects on breast cancer risk
(Ginsburg et al.,2 0 0 9 ). However, a recent epidemiology study
showed that smoking is signiﬁcantly associated with increased
breast cancer risk when BRCA mutant women smoked for 5 or
more years before the age of 50 (Breast Cancer Family Registry,
2008). The frequency of BRCA1 mutations among human
breast cancer patients is not very high (less than 5%), but the
majority of women with familial breast cancer harbor a mutation
either in BRCA1 or BRCA2. More importantly, emerging
evidence suggests that a high frequency of hypermethylation on
the BRCA1 promoter signiﬁcantly decreases the expression
level of BRCA1 mRNA and protein in sporadic breast cancer
(Ali et al.,2 0 1 1 ; Galizia et al.,2 0 1 0 ; Jing et al.,2 0 1 0 ; Mueller
and Roskelley 2003; Rice et al.,2 0 0 0 ). A recent study shows
that 36.7% (25 of 68 tumors) of sporadic breast cancer have
hypermethylated BRCA1 promoters (Veeck et al.,2 0 1 0 ). Thus,
a large portion of sporadic breast cancers express low levels of
BRCA1 and could be susceptible to environmental factors that
require fully functional BRCA1 for detoxiﬁcation. Thus, future
studies of all aspects of BRCA1 function will elucidate its role in
environmental risk for all women.
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